None
Quote | Guardant Health Inc. (NASDAQ:GH)
Last: | $17.22 |
---|---|
Change Percent: | -4.86% |
Open: | $17.71 |
Close: | $18.10 |
High: | $17.86 |
Low: | $16.95 |
Volume: | 1,151,179 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Guardant Health Inc. (NASDAQ:GH)
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company’s ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / ...
Message Board Posts | Guardant Health Inc. (NASDAQ:GH)
Subject | By | Source | When |
---|---|---|---|
GH(-34%/AH)reports_results_of Shield ctDNA(liquid biopsy)diagnostic_for co | DewDiligence | investorshub | 12/16/2022 12:06:13 AM |
I'm still feeling very good about owning this | jerseyboy | investorshub | 04/01/2021 10:10:37 PM |
I like the nice, gradual, consistent rise in | jerseyboy | investorshub | 12/21/2020 10:49:18 PM |
So am I. This is THE company I | jerseyboy | investorshub | 11/27/2020 12:09:11 AM |
2-3 years I'm thinking this is @ 3-5X | PR_12 | investorshub | 11/12/2020 3:48:48 PM |
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company’s ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / ...
New research demonstrates value of epigenomic analysis and methylation sequencing with Guardant liquid biopsy portfolio across continuum of cancer care New data show strong performance of Guardant Reveal™ in detection and quantification of residual disease in early-stage breast can...